About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hematologists Set the Stage for Market Disruption as Next-Gen Hemophilia Therapies Gain Traction

By: via GlobeNewswire

EXTON, PA, June 12, 2025 (GLOBE NEWSWIRE) -- As the hemophilia landscape continues to transform, new research from Spherix Global Insights reveals a market on the cusp of significant evolution driven by innovation, physician receptivity, and an increasingly nuanced approach to patient care. The latest Market Dynamix™: Hemophilia (EU) 2025 report, based on feedback from 160 hematologists across the UK, France, Germany, Italy, and Spain, illuminates shifting treatment preferences and the widening role for advanced therapeutic options across hemophilia A and B.  

The study captures a broadening treatment mindset in a market historically dominated by factor replacement therapies. Although conventional agents have provided stability for many patients, Spherix data highlight an increasingly urgent unmet need, particularly among patients with inhibitors. In fact, patients with inhibitors represent the group for whom hematologists see the greatest opportunity for innovation. Products such as Alhemo (Novo Nordisk) and Qfitlia (Sanofi) are already entering the physician consciousness as promising options, with early prescribing experiences for Alhemo in Germany showing favorable clinical feedback.  

Importantly, European hematologists are signaling readiness to embrace novel mechanisms that deliver sustained efficacy and reduce treatment burden. Beyond Alhemo and Hympavzi, there is rising anticipation for agents like Qfitlia and Mim8 (Novo Nordisk). Gene therapy, once seen as aspirational, is becoming a more realistic consideration, especially in hemophilia B where therapeutic alternatives remain limited. CSL Behring’s Hemgenix and BioMarin’s Roctavian are drawing interest, albeit tempered by concerns around cost and long-term outcomes.  

Spherix data reveal a market increasingly driven not just by efficacy but by lifestyle alignment and convenience. This reflects a maturation of brand expectations, where baseline efficacy is presumed and differentiation hinges on quality-of-life enhancements. The move away from standard half-life (SHL) and even extended half-life (EHL) products is evident, particularly in hemophilia A, where agents like Hemlibra (Roche/Genentech) and Altuvoct/Altuviiio (Sanofi) are rapidly becoming standard practice.  

Underlying these trends is a broader shift in therapeutic philosophy: goals focus less and less on symptom control (which is assumed) while disease modification becomes centrally important, mirroring changes seen in other chronic specialty markets. Hematologists are prepared to make transitions, especially when options can seamlessly accommodate inhibitor development without requiring treatment change. 

For Hympavzi, Alhemo, and Qfitlia, upcoming Launch DynamixTM tracking among US hematologists (available June 13th) underlines similar themes, with projected prescribing steadily rising for these novel agents. Additional metrics included in launch tracking include impact of product features and manufacturer programs on prescribing, assessment of likely patient groups for initial product trialing, and perspectives on which brand(s) are likely displaced by newer market entrants.  

Ultimately, as the treatment paradigm continues to evolve, biopharma stakeholders seeking success in the hemophilia space will need to align not only with clinical outcomes but also with patient-centric attributes now prioritized in physician decision-making. 

Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents. 

Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand. 

About Spherix Global Insights  

Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.  

The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community.  

As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.  

To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.   

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com  

NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. 


Sarah Hendry, Hematology Franchise Head
Spherix Global Insights
4848794284
sarah.hendry@spherixglobalinsights.com

More News

View More
Pfizer is Locking in New Growth Through a New Acquisition
Via MarketBeat
Topics Artificial Intelligence
Tickers MTSR PFE
Copper Giant Freeport Slumps but Analysts See 33% Upside
Via MarketBeat
Tickers FCX SCCO
The BYD Opportunity: Tesla-Like Growth at a Fraction of the Price
Via MarketBeat
Topics Electric Vehicles
Tickers BYDDY LI TSLA
3 Reasons CoreWeave Could Be the Hottest AI Stock in Q4
Via MarketBeat
Topics Artificial Intelligence
Tickers CRWV NVDA
Accenture: Undervalued GenAI Leader or Snake Eating its Own Tail?
Via MarketBeat
Tickers ACN IBM
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.